EP3838267A1 - Comprimés d'edoxaban - Google Patents

Comprimés d'edoxaban Download PDF

Info

Publication number
EP3838267A1
EP3838267A1 EP19383144.3A EP19383144A EP3838267A1 EP 3838267 A1 EP3838267 A1 EP 3838267A1 EP 19383144 A EP19383144 A EP 19383144A EP 3838267 A1 EP3838267 A1 EP 3838267A1
Authority
EP
European Patent Office
Prior art keywords
tablet
starch
lactose
diluent
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19383144.3A
Other languages
German (de)
English (en)
Inventor
Orazio Luca Strusi
José Vicente HERNÁNDEZ BALLESTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohorm SL
Original Assignee
Biohorm SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohorm SL filed Critical Biohorm SL
Priority to EP19383144.3A priority Critical patent/EP3838267A1/fr
Priority to BR112022012063A priority patent/BR112022012063A2/pt
Priority to KR1020227024909A priority patent/KR20220118510A/ko
Priority to CN202080088448.7A priority patent/CN114845703A/zh
Priority to CA3165090A priority patent/CA3165090A1/fr
Priority to EP20838009.7A priority patent/EP4076406A1/fr
Priority to JP2022537578A priority patent/JP2023506991A/ja
Priority to MX2022007707A priority patent/MX2022007707A/es
Priority to PCT/EP2020/087055 priority patent/WO2021123192A1/fr
Publication of EP3838267A1 publication Critical patent/EP3838267A1/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the present invention relates to solid pharmaceutical formulations comprising edoxaban as an active ingredient, in particular relating to tablets for oral administration, and to a process to prepare the same.
  • Edoxaban is the common name of the chemical compound N'-(5-chloropyridin-2-yl)- N -[(1 S ,2 R ,4 S )-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4 H -[1,3]thiazolo [5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide, and has the chemical structure shown below.
  • anti-coagulant drug namely a direct factor Xa inhibitor, a class of anti-coagulants comprising other drugs ("xabans”) such as rivaroxaban, apixaban and betrixaban, which was developed as an alternative to classic anti-coagulants such as heparin(s) and warfarin, due to the limitations in administration routes (heparins are injectable), and/or narrow therapeutic window (in the case of warfarin).
  • Edoxaban is a basic compound, and thus can be solubilized in strong acidic aqueous solution, however when the pH of the aqueous media is shifted to less acidic, neutral or basic values, the dissolution profile of edoxaban diminishes considerably.
  • patent document EP 2 140 867 A1 discloses oral solid dosage forms, namely tablets coated or not, comprising edoxaban together with a sugar alcohol (mannitol) and/or a water-swelling additive, and other excipients.
  • mannitol sugar alcohol
  • use of sugar alcohols may be problematic in patients showing intolerance against these compounds, such as mannitol.
  • compositions where the sugar alcohol is replaced by other excipients such as a combination of a saccharide (lactose), and a starch (cornstarch) the dissolution profile of the resulting compositions at pH 4 (strong acidic medium) is not satisfactory.
  • Patent document EP 2 548 556 A1 discloses that keeping the water content during granulation of edoxaban-containing material to 10% or less, leads to an improved dissolution profile in the neutral region of the pH scale. However, this improvement is only obtained in formulations having a sugar alcohol in its composition. As mentioned above, many patients show intolerance against sugar alcohols, such as mannitol. Yet, it is further known that these excipients also increase the gastrointestinal motility, leading to a decrease in drug absorption, which involves the risk of lower efficacy of the therapeutic ingredient.
  • Patent document EP 3 177 290 A1 discloses tablet compositions comprising edoxaban in combination with a water-soluble vinylpyrrolidone polymer (copovidone, povidone) and a cellulose ether, free of a sugar alcohol.
  • a water-soluble vinylpyrrolidone polymer copovidone, povidone
  • a cellulose ether free of a sugar alcohol.
  • a water-soluble vinylpyrrolidone polymer affects the stability of the tablets. Because of its high peroxide content, vinylpyrrolidone polymers tend to oxidatively degrade the active ingredient and the excipients causing lower tablet stability, which results eventually in lower therapeutic efficacy.
  • a tablet formulation comprising edoxaban or a pharmaceutically acceptable salt thereof, a first diluent and a second diluent, wherein said second diluent is different from said first diluent, have an adequate dissolution profile, when compared with other tablet formulations known in the art.
  • a second aspect of the present invention refers to a process for the preparation of a tablet formulation according to the first aspect.
  • a tablet comprising edoxaban or a pharmaceutical acceptable salt thereof, a lactose, as a first diluent and a starch, as a second diluent in a weight ratio equal or greater than 2.5:1, shows a good to excellent dissolution profile.
  • edoxaban and two diluents have unacceptable dissolution rates, requiring more than 30 minutes to dissolve 85% of the active ingredient, whereas the generally desired dissolution rate is 90% in less than 15 minutes.
  • the present invention refers to a tablet composition
  • a tablet composition comprising edoxaban or a pharmaceutically acceptable salt thereof, a first diluent and a second diluent, wherein said second diluent is different from said first diluent.
  • the present invention refers to a tablet composition
  • a tablet composition comprising edoxaban or a pharmaceutically acceptable salt thereof, a lactose as a first diluent, and a starch as a second diluent.
  • the weight ratio of lactose, as first diluent to starch, as second diluent, in the tablets according to the present invention is equal or greater than 2.5:1 (lactose:starch), preferably equal or greater than 2.7:1, more preferably equal or greater than 2.9:1, more preferably equal or greater than 3:1, even more preferably equal or greater than 3.2:1, even more preferably equal or greater than 3.3:1, even more preferably equal or greater than 3.5:1, even more preferably equal or greater than 3.7:1 and even more preferably equal or greater than 4:1 (lactose: starch).
  • the weight ratio of lactose, as a first diluent, to starch, as a second diluent, in the tablets according to the present invention is comprised between 2.5:1 and 20:1 (lactose:starch), preferably between 2.5:1 and 10:1, more preferably between 2.7:1 and 10:1, more preferably between 2.9:1 and 10:1, even more preferably between 3:1 and 10:1, even more preferably between 3.2:1 and 10:1, even more preferably between 3.3:1 and 10:1, even more preferably between 3.3:1 and 8:1, even more preferably between 3.5:1 and 8:1, even more preferably between 3.7:1 and 8:1, and even more preferably between 4:1 and 8:1.
  • the tablet of the present invention comprises edoxaban or a pharmaceutically acceptable salt thereof, a lactose as a first diluent, and a starch as a second diluent, wherein the starch is pregelatinized starch, and wherein the weight ratio of a lactose to pregelatinized starch is about 4:1.
  • the lactose is lactose monohydrate.
  • the tablets according to the first aspect do not comprise sugar alcohols.
  • Sugar alcohols are known to cause intolerances and may result in lower therapeutic efficacy.
  • the tablets according to the first aspect do not comprise soluble vinylpyrrolidone polymers, such as povidone and copovidone due to their high peroxide content degrade a pharmaceutical composition over time.
  • the tablets according to the invention comprise lactose and starch as the sole diluents.
  • the tablets according to the invention do not comprise sugar alcohols and do not comprise soluble vinylpyrrolidone polymers.
  • the tablets according to the first aspect comprise lactose and starch but do not comprise sugar alcohols.
  • the tablets according to the first aspect comprise lactose and starch but do not comprise soluble vinylpyrrolidone polymers, such as povidone and copovidone.
  • the tablets according to the first aspect comprise lactose, as a first diluent, and a starch, as a second diluent, in a weight ratio lactose: starch of equal or greater than 2.5:1, preferably equal or greater than 2.7:1, more preferably equal or greater than 2.9:1, more preferably equal or greater than 3:1, even more preferably equal or greater than 3.2:1, even more preferably equal or greater than 3.3:1, even more preferably equal or greater than 3.5:1, even more preferably equal or greater than 3.7:1 and even more preferably equal or greater than 4:1; with one or more of the following provisos: i) the tablets do not comprise sugar alcohols; ii) the tablets do not comprise water soluble vinylpyrrolidone polymers, such as povidone and copovidone; iii) the tablets contain lactose and starch as the two sole diluents; and iv) the tablets contain only one binder
  • the tablets according to the first aspect comprise one or more binders.
  • binders Preferably, only one binder is used, for example hydroxypropyl cellulose, and not two or more. This results in pharmaceutical compositions requiring less ingredients, which results in less complicated compositions that can be manufactured at lower costs.
  • an "adequate dissolution profile” refers to tablets having a dissolution profile, wherein at least about 90% of the active ingredient dissolves in the test media, in less than 15 minutes, preferably in less than 10 minutes, more preferably in less than 5 minutes.
  • the tablets have a dissolution profile wherein at least 90% of the active ingredient dissolves in the test media, in less than 15 minutes, preferably in less than 10 minutes, more preferably in less than 5 minutes.
  • the method used for obtaining dissolution profiles according to the present invention is as follows: A paddle dissolution test is carried out, wherein a tablet is added to 900 mL of acetate buffer at pH 4.0 at 37 ⁇ 0.5°C with a rotation speed of 50 rpm. Samples are taken every 5 minutes.
  • edoxaban is used to encompass both the free base N '-(5-chloropyridin-2-yl)- N -[(1 S ,2 R ,4 S )-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4 H -[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide as well as the pharmaceutically acceptable salts thereof.
  • edoxaban is used in the form of its tosylate salt, more preferably in the form of the monohydrate of said tosylate salt.
  • the tablet according to present invention further comprises additional pharmaceutically acceptable excipients selected from the group comprising diluents, binder, disintegrants, lubricants, and optionally colorants, sweeteners or aromas.
  • Non-limiting examples of a suitable lactose for the tablets according to the present invention are: alfa-lactose, beta-lactose, lactose monohydrate, anhydrous lactose, and/or mixtures thereof.
  • the lactose is lactose monohydrate.
  • the suitable lactose may be comprised in the tablet in an amount of 50 to 75 % by weight, preferably 50 to 70 % by weight, and more preferably 55 to 70 % by weight.
  • Non-limiting examples of suitable starches for the tablets according to the present invention are: cornstarch, potato starch, rice starch, pregelatinized starch, semi-digested starch, and/or mixtures thereof.
  • the starch is pregelatinized starch.
  • the suitable starch may be comprised in the tablet in an amount of 6.0 to 25 % by weight, preferably 6.0 to 21 % by weight, and more preferably 6.0 to 17 % by weight.
  • Non-limiting examples of other suitable diluents are calcium phosphate, calcium hydrogen phosphate, di-calcium phosphate hydrate and/or mixtures thereof, with the proviso that said additional diluent is only used, when no povidone and no copovidone is present in the composition.
  • the suitable other diluent may be comprised in the tablet in an amount of 0 to 25 % by weight.
  • Non-limiting examples of suitable binders for the tablets of the present invention are microcrystalline cellulose, hydroxypropyl cellulose, sodium alginate, chitosan, hydroxypropyl methylcellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose, carboxymethylhydroxyethyl cellulose and/or mixtures thereof.
  • the binder is hydroxypropyl cellulose.
  • the suitable binder(s) may be comprised in the tablet in an amount of 0.5 to 7 % by weight, preferably 1.5 to 5 % by weight, and more preferably 2.5 to 5 % by weight.
  • Non-limiting examples of suitable disintegrants for the tablets of the present invention are sodium starch glycolate, calcium silicate, sodium croscarmellose, and/or mixtures thereof.
  • the disintegrant is sodium starch glycolate.
  • Sodium starch glycolate is not considered being a diluent, and thus is not a starch as defined above.
  • the suitable disintegrant(s) may be comprised in the tablet in an amount of 0.1 to 8 % by weight, preferably 0.5 to 7 % by weight, and more preferably 1 to 5 % by weight.
  • Non-limiting examples of suitable lubricants for the tablets of the present invention are sodium benzoate, stearic acid, magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, glyceryl behenate, glyceryl monostearate, and/or mixtures thereof.
  • the lubricant is magnesium stearate.
  • the suitable lubricant(s) may be comprised in the tablet in an amount of 0.05 to 2 % by weight, preferably 0.1 to 2 % by weight, and more preferably 0.5 to 1.5 % by weight.
  • lactose is lactose monohydrate
  • the starch is pregelatinized starch
  • the binder is hydroxypropyl cellulose
  • the disintegrant is sodium starch glycolate
  • the lubricant is magnesium stearate.
  • the tablet according to present invention further comprises a coating.
  • coatings comprise coating agents containing for example poly(vinyl alcohol) (PVA), hydroxypropyl methylcellulose (HPMC) or polyethyleneglycol-poly(vinyl alcohol) (PEG-PVA) graft copolymer.
  • PVA poly(vinyl alcohol)
  • HPMC hydroxypropyl methylcellulose
  • PEG-PVA polyethyleneglycol-poly(vinyl alcohol)
  • immediate release type coatings containing a polymer, a plasticizer and a pigment in a dry concentrate, such as Opadry® from Colorcon may be used.
  • the invention further relates to the tablets according to the present invention for use as a medicament in the prevention and/or treatment of thrombosis or embolism.
  • the invention also relates to the use of tablets according to the present invention in the manufacture of a medicament for the prevention and/or treatment of thrombosis or embolism.
  • the invention also relates to a method of prevention and/or treatment of thrombosis or embolism, comprising administering to said subject a tablet according to the present invention.
  • the present invention relates to a process for the preparation of the tablets according to the first aspect, comprising:
  • the process for the preparation of the tablets according to the first aspect comprises the steps of:
  • the process for the preparation of the tablets according to the first aspect comprises the steps of:
  • the process for the preparation of the tablets according to the first aspect wherein the tablets comprise a binder comprises the steps of:
  • the process for the preparation of tablets comprising a binder and a disintegrant comprises the steps of:
  • the above mentioned process further comprises:
  • lactose is lactose monohydrate
  • the starch is pregelatinized starch
  • the binder is hydroxypropyl cellulose
  • the disintegrant is sodium starch glycolate
  • the lubricant is magnesium stearate.
  • the first diluent preferably a lactose
  • the preparation of the mixture of step i) is carried in two steps; in the first step edoxaban, a first portion of the first diluent, the second diluent, a first portion of the binder, and a first portion of the disintegrant are mixed to obtain a first mixture and in a second step the rest (second portion) of the first diluent is added to the first mixture and further mixed to obtain a second mixture.
  • the first portion of the first diluent is added to the mixer as the first material of the mixture and the second portion of the first diluent is added as the last material of the mixture. This is known as the "sandwich method" and has the advantage that the resulting mixture shows good homogeneity of the blend after the step of mixing.
  • edoxaban tosylate monohydrate 40.41 mg are mixed in a double cone blender operated at 18 rpm during 25 minutes with 60.495 mg of lactose monohydrate (first portion of first diluent), 30.00 mg of pregelatinized starch, 2.56 mg of hydroxypropyl cellulose (first portion of binder), 2.09 mg of sodium starch glycolate (first portion of disintegrant) and 60.495 mg of lactose monohydrate (second portion of first diluent). The mixture is then wet-granulated in a fluid bed at 30°C with an aqueous solution comprising 4.98 mg of hydroxypropyl cellulose (second portion of binder) in 7.54 mg of water.
  • the granules are then dried in a fluid bed and milled in a conical mill at 1750 rpm using a 0.9 mm sieve.
  • the resulting powder is mixed with 6.27 mg of sodium starch glycolate (second portion of disintegrant) in a double cone blender operated at 18 rpm for 15 minutes.
  • 1.70 mg of magnesium stearate are added to the blender which is further operated at 18 rpm for 5 minutes and the resulting mixture is tabletted in a rotary tabletting press operated at 90 N and a speed of 50 tablets/minutes.
  • the tablets were then coated with Opadry® 03F220132 Yellow in a fully perforated drum.
  • Examples 2 and 3 were manufactured in the same way, except for using the quantities as shown in table 1 and both examples 2 and 3 were not coated.
  • dissolution profiles of examples 1, 2 and 3, having a lactose:starch ratio greater than 2.5:1, have good to excellent dissolution properties.
  • Comparative example 1 has been carried out following experiment C from patent document EP 2 140 867 A1 , as follows: ingredients shown in Table 2, excepting hydroxypropyl cellulose and magnesium stearate, were mixed by means of a mortar, and the mixture was granulated by use of aqueous hydroxypropyl cellulose solution. The thus-produced granules were mixed with magnesium stearate, to thereby yield granules were compressed into tablets using round shaped dies with a diameter of 8.0mm and punches at 7.8 kN of compression force, to thereby yield tablets of interest.
  • this composition does not have good dissolution properties, having a more slow dissolution profile.
EP19383144.3A 2019-12-19 2019-12-19 Comprimés d'edoxaban Withdrawn EP3838267A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP19383144.3A EP3838267A1 (fr) 2019-12-19 2019-12-19 Comprimés d'edoxaban
BR112022012063A BR112022012063A2 (pt) 2019-12-19 2020-12-18 Comprimidos de edoxabana
KR1020227024909A KR20220118510A (ko) 2019-12-19 2020-12-18 에독사반 정제
CN202080088448.7A CN114845703A (zh) 2019-12-19 2020-12-18 艾多沙班片剂
CA3165090A CA3165090A1 (fr) 2019-12-19 2020-12-18 Comprimes d'edoxaban
EP20838009.7A EP4076406A1 (fr) 2019-12-19 2020-12-18 Comprimés d'edoxaban
JP2022537578A JP2023506991A (ja) 2019-12-19 2020-12-18 エドキサバン錠剤
MX2022007707A MX2022007707A (es) 2019-12-19 2020-12-18 Comprimidos de edoxaban.
PCT/EP2020/087055 WO2021123192A1 (fr) 2019-12-19 2020-12-18 Comprimés d'edoxaban

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19383144.3A EP3838267A1 (fr) 2019-12-19 2019-12-19 Comprimés d'edoxaban

Publications (1)

Publication Number Publication Date
EP3838267A1 true EP3838267A1 (fr) 2021-06-23

Family

ID=69411195

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19383144.3A Withdrawn EP3838267A1 (fr) 2019-12-19 2019-12-19 Comprimés d'edoxaban
EP20838009.7A Pending EP4076406A1 (fr) 2019-12-19 2020-12-18 Comprimés d'edoxaban

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20838009.7A Pending EP4076406A1 (fr) 2019-12-19 2020-12-18 Comprimés d'edoxaban

Country Status (8)

Country Link
EP (2) EP3838267A1 (fr)
JP (1) JP2023506991A (fr)
KR (1) KR20220118510A (fr)
CN (1) CN114845703A (fr)
BR (1) BR112022012063A2 (fr)
CA (1) CA3165090A1 (fr)
MX (1) MX2022007707A (fr)
WO (1) WO2021123192A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114469881A (zh) * 2022-03-14 2022-05-13 河北坤安药业有限公司 一种硝酸甘油片及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022129535A1 (fr) 2020-12-18 2022-06-23 Krka, D.D., Novo Mesto Formulation d'edoxaban ne contenant pas d'alcools de sucre

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1405852A1 (fr) 2001-06-20 2004-04-07 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
EP2140867A1 (fr) 2007-03-29 2010-01-06 Daiichi Sankyo Company, Limited Composition pharmaceutique
EP2548556A1 (fr) 2010-03-19 2013-01-23 Daiichi Sankyo Company, Limited Procédé d'amélioration de l'aptitude à se dissoudre d'un anticoagulant
CN103919746A (zh) * 2014-04-17 2014-07-16 山东省医药工业研究所 依度沙班缓释片及其制备方法
EP3177290A1 (fr) 2014-08-06 2017-06-14 Sandoz AG Compositions pharmaceutiques d'édoxaban
CN108743556A (zh) * 2018-02-02 2018-11-06 重庆植恩药业有限公司 一种依度沙班片剂及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3744320A1 (fr) * 2019-05-29 2020-12-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition de comprimé pharmaceutique comprenant de l'edoxaban

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1405852A1 (fr) 2001-06-20 2004-04-07 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
EP2140867A1 (fr) 2007-03-29 2010-01-06 Daiichi Sankyo Company, Limited Composition pharmaceutique
EP2548556A1 (fr) 2010-03-19 2013-01-23 Daiichi Sankyo Company, Limited Procédé d'amélioration de l'aptitude à se dissoudre d'un anticoagulant
CN103919746A (zh) * 2014-04-17 2014-07-16 山东省医药工业研究所 依度沙班缓释片及其制备方法
EP3177290A1 (fr) 2014-08-06 2017-06-14 Sandoz AG Compositions pharmaceutiques d'édoxaban
EP3177290B1 (fr) * 2014-08-06 2018-06-20 Sandoz AG Compositions pharmaceutiques d'edoxaban
CN108743556A (zh) * 2018-02-02 2018-11-06 重庆植恩药业有限公司 一种依度沙班片剂及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114469881A (zh) * 2022-03-14 2022-05-13 河北坤安药业有限公司 一种硝酸甘油片及其制备方法

Also Published As

Publication number Publication date
CA3165090A1 (fr) 2021-06-24
BR112022012063A2 (pt) 2022-08-30
MX2022007707A (es) 2022-07-19
EP4076406A1 (fr) 2022-10-26
WO2021123192A1 (fr) 2021-06-24
JP2023506991A (ja) 2023-02-20
CN114845703A (zh) 2022-08-02
KR20220118510A (ko) 2022-08-25

Similar Documents

Publication Publication Date Title
KR101552033B1 (ko) 약학 조성물
EP2974720B1 (fr) Préparation à libération prolongée de mosapride pour fournir des effets cliniques pharmacologiques avec une administration une fois par jour
KR100836960B1 (ko) 새로운 나이아신 제어방출형 제제
KR100780553B1 (ko) 메트포르민 서방정 및 그의 제조방법
KR101792299B1 (ko) 항응고제의 용출 개선 방법
EA023529B1 (ru) Способ получения твердых лекарственных форм солифенацина и его фармацевтически приемлемых солей для перорального введения
WO2013026553A1 (fr) Composition comprenant de l'edoxaban
EP3838267A1 (fr) Comprimés d'edoxaban
CN109875972B (zh) 一种奥美沙坦酯氨氯地平药物组合物
KR102467265B1 (ko) 분자량분포 특성을 조절한 모사프리드 함유 서방제제
EP3177290B1 (fr) Compositions pharmaceutiques d'edoxaban
EP2804588B1 (fr) Procédé de préparation de compositions de cinacalcet destinées à la fabrication directe de comprimés
KR102465629B1 (ko) 1일 1회 경구투여하는 모사프리드 함유 서방제제
EP3002006A1 (fr) Composition pharmaceutique capable de l'incorporation de febuxostat dans les modifications cristallines F10, II, G et A
EP3219309A1 (fr) Compositions pharmaceutiques comprenant combinaisons à dose fixe de amlodipine, de candesartan cilexetil et de hydrochlorothiazide pour le traitement de l'hypertension
EP2696857A1 (fr) Composition pharmaceutique comprenant du bosentan
JP5644167B2 (ja) 溶出改善されたケトチフェン又はその塩を含有する固形製剤
EP3911305B1 (fr) Procédé de fabrication d'une composition pharmaceutique comprenant du néfopam et de l'acétaminophène et composition pharmaceutique ainsi obtenue
EP3335702A1 (fr) Compositions pharmaceutiques comprenant de l'omarigliptine
EP2181705A1 (fr) Formulation à libération prolongée de gliclazide
JP2009538905A (ja) 感湿性薬物を含んで成る安定性製剤及びその製造方法
CN112263555B (zh) 一种替米沙坦口崩片及其制备方法
EP3173075B1 (fr) Préparation pharmaceutique combinée constituée d'un inhibiteur ace et diurétique de l'anse
JP2023058097A (ja) エドキサバン含有医薬組成物
KR20230084974A (ko) 다파글리플로진 프로판디올 수화물을 포함하는 습식 과립 조성물, 과립물, 정제, 이들의 제조 방법, 및 상기 제조 방법으로 제조된 과립물 또는 정제

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20211224